Various studies have indicated that CEUS is a strong tool for monitoring radiofrequency ablation (RFA) procedures in percutaneous, laparoscopic, or intraoperatively-guided tumor ablations.
Repeating CEUS after ablation allows the vascular activity in the tumor and its surroundings before and after RFA to be compared. If CEUS indicates residual vital tumor tissue after an ablation, the procedure may be extended or repeated until treatment is considered sufficient.
In the USA, contrast-enhanced ultrasound has not been market cleared by the FDA, with the exception of only select cardiac imaging applications.